Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $28.18
Previous CloseN/A
Volume723.92K
Average Volume (3M)3.45M
Market Cap
$819.86M
Enterprise Value$796.31M
Total Cash (Recent Filing)-$9.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.60
Next Earnings
May 01, 2025EPS Estimate
-1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.25
Shares Outstanding103,517,460
10 Day Avg. Volume3,522,941
30 Day Avg. Volume3,454,536
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.10
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.76
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$34.00Price Target Upside309.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsIn a Phase I trial, nex-z elicited an 89% reduction in TTR over a 28-day span, which is competitive with vutrisiran’s 70% TTR reduction over a 45-day span.
Regulatory ApprovalIntellia's CRISPR-based TTR silencing therapy nexiguran-ziclumeran (nex-z; NTLA-2001) was granted regenerative medicine advanced therapy (RMAT) designation by the FDA for the treatment of ATTR-cardiomyopathy (ATTR-CM) and ATTR-polyneuropathy (ATTR-PN).
Bears Say
Commercial OutlookThe commercial outlook for nex-z after approval is uncertain due to competitive threats.
Market CompetitionCompetition in the ATTR-CM space is increasing due to aggressive development plans from competitors like Alnylam.
---
Ownership Overview
1.59% Insiders
17.92% Mutual Funds
0.37% Other Institutional Investors
49.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $5.90 and its highest was $28.18 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $819.86M.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 8 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Feb 27, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.331 by $0.061.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -1.28.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 103,517,460 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.331. Following the earnings report the stock price went up 0.556%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
---
Intellia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (309.15% Upside)
$34.00 (309.15% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 475.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $734.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.28%
12-Months-Change
Fundamentals
Return on Equity
-54.00%
Trailing 12-Months
Asset Growth
-8.45%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
---
NTLA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Intellia Therapeutics reported strong progress in its clinical pipeline, particularly with Phase III enrollment for HAE and ATTR amyloidosis, and demonstrated a solid financial position to support ongoing operations. However, the company faced increased operating expenses and restructuring challenges, including program discontinuation and workforce reductions.Read More>---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$34.00
▲(309.15% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
13/38 ratings generated profit
1 Year Average Return
+83.99%
reiterated a buy rating 5 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +83.99% per trade.
---